stage IV adrenocortical carcinoma

Known as: adrenocortical carcinoma, metastatic, carcinoma, adrenocortical stage IV, stage IV adrenocortical cancer 
Stage IV includes: (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); (Any T, Any N, M1). T3: Tumor of any size with local invasion, but not invading adjacent… (More)
National Institutes of Health

Related topics

Related topics

19 relations
Abdominal CavityAdrenal CortexAdrenal Cortical CellAdrenal Glands
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment
Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7-2.0 cases/million habitants/year. The diagnosis of… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
BACKGROUND Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment options are available. Linsitinib (OSI… (More)
  • table 2
  • table 3
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Genomic landscape of paediatric adrenocortical tumours.
Paediatric adrenocortical carcinoma is a rare malignancy with poor prognosis. Here we analyse 37 adrenocortical tumours (ACTs) by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
Background:Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective systemic… (More)
  • table 1
  • figure 1
Is this relevant?
2012
2012
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors.
CONTEXT It is not known whether there are any DNA methylation alterations in adrenocortical tumors. OBJECTIVE The objective of… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Prognostic parameters of metastatic adrenocortical carcinoma.
CONTEXT Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized. OBJECTIVE The objective of… (More)
Is this relevant?
2007
2007
Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
PURPOSE Allelic losses [loss of heterozygosity (LOH)] at the 17p13 locus are frequent (85%) in adrenocortical cancers. The tumor… (More)
Is this relevant?
2006
2006
Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
CONTEXT Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases.
BACKGROUND The current study was performed to analyze the feasibility, safety, imaging appearance, and short-term efficacy of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1999
1999
Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16.
To identify chromosomal regions that may contain loci for tumor suppressor genes involved in adrenocortical tumor development, a… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?